- Home
- NCNA vs BGLC Comparison
NCNA vs BGLC Comparison
Compare NCNA & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCNA | BGLC |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United Kingdom | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 10.1M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | NCNA | BGLC |
|---|---|---|
| Price | $2.24 | $2.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 66.6K | 33.1K |
| Earning Date | 03-19-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $9,465,006.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.21 |
| 52 Week Low | $2.07 | $1.92 |
| 52 Week High | $268.00 | $15.60 |
Technical Indicators
Market Signals| Indicator | NCNA | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 26.46 | 30.43 |
| Support Level | $2.08 | $1.92 |
| Resistance Level | $2.26 | $2.91 |
| Average True Range (ATR) | 0.19 | 0.20 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 4.72 | 19.47 |
Price Performance
Historical ComparisonAbout NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About BGLC BioNexus Gene Lab Corp
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.